Formulary and Clinical Guideline Document Pharmacy Department Medicines Management Services

Size: px
Start display at page:

Download "Formulary and Clinical Guideline Document Pharmacy Department Medicines Management Services"

Transcription

1 Formulary and Clinical Guideline Document Pharmacy Department Medicines Management Services DRIVING AND MENTAL HEALTH CONDITIONS AND TREATMENTS General information Driving while impaired by a physical or mental health condition or the influence of drugs can seriously impact on safe control of a vehicle and increase the risk of accidents. Mental disorders can affect judgement, concentration and reaction times. Pharmacological treatments can reduce the driving-related risks associated with mental disorders; however, they can also impair driving skills due to the side-effect profile. Drugs can impair driving performance as a consequence of adverse effects such as drowsiness, poor coordination, impaired or slowed thinking, dizziness, or visual problems Alcohol, even in small amounts, will significantly potentiate the effects of medication on the central nervous system impairing safe driving It is an offence to drive or attempt to drive whilst unfit to do so due to alcohol and/or drugs, whether illegal drugs or legally prescribed medicines. All drugs that act on the central nervous system can impair alertness, concentration and driving performance. This is particularly so at initiation of treatment and when the dose is increased or if another drug is added that could also impair driving ability. Driving must be avoided if adversely affected From March 2015, it is now an offence to drive with certain specified controlled drugs above specified limits in the blood. These include illegal drugs and medicines. Some medical conditions can affect a person s fitness to drive and in some cases need to be notified to the Driver and Vehicle Licensing Agency DVLA. Drivers with psychiatric illnesses are usually safer when well and on regular psychotropic medication than when they are ill. However, inadequate treatment or lack of compliance may render the driver impaired by both illness and medication. Notification to the DVLA Doctors and other healthcare professionals should: advise individual drivers of the impact of their condition on fitness to drive; advise the individual on their legal requirement to notify the DVLA; treat, manage and monitor the individual s condition with on-going consideration of the impact on driving. Health professionals prescribing or dispensing medication should consider the risk associated with that medicine or combination of medicines, and driving and take the opportunity to appropriately advise their patients. It is the duty of the license holder or license applicant to notify DVLA of any illness, injury or medication, which may affect safe driving and comply with any requirements indicated by the DVLA including any periodic medical reviews. They should also adhere, with ongoing consideration of fitness to drive, to prescribed medical treatment, and to monitor and manage the condition and any adaptations. On occasions however, there are circumstances in which the license holder cannot, or will not notify the DVLA. In such cases, it may be necessary for the healthcare professional to contact the DVLA if there is concern for road safety for the benefit of the individual and the wider public. Medico-legal implications make it necessary for doctors and psychiatrists to be aware of the GMC guidance and also advice of the Royal College of Psychiatrists. Driving and Mental Health Conditions and Treatments Next Review June

2 Medical conditions, medication and driving Driving is a complex information processing task which can be divided in 3 steps: perception (detection and identification), decision and reaction which may be affected by mental health disorders due to : o Poor cognition reduced attention, memory problems o Impaired motor function slower reaction times, loss of coordination o Altered thoughts and behaviours, impaired judgement including ability to predict and anticipate o Emotional states eg agitation, irritation, depression have a detrimental influence on perception and information processing Anyone with a medical condition likely to cause a sudden disabling event at the wheel, or who is unable to control their vehicle safely for any other reason, must not drive. Medical conditions such as diabetes mellitus, cardiac disorders, epilepsy, visual impairments and renal and respiratory conditions are subject to DVLA rules for fitness to drive. The rules relating to mental health conditions and alcohol or substance misuse and dependence are summarised in the tables below. If psychiatric illness has been associated with substance misuse, continued misuse contraindicates driving and licensing. The latest guidance is always available at: Medication can improve driving performance in individuals with well-controlled conditions but side effects must be considered. Effects of medication that can impair driving ability include: o Sedation and dizziness o Concentration difficulties o Postural hypotension o Blurred vision o Impaired coordination o Extrapyramidal adverse effects, eg muscle stiffness Drivers taking prescribed drugs subject to the drug-driving legislation will need to be advised to carry confirmation that these were prescribed by a registered medical practitioner. Licence holders are legally required to notify the DVLA of any injury or illness that would have a likely impact on safe driving ability. By law, driving licences are classified into Group 1 (motorcycles and cars) and Group 2 (heavy goods vehicles and passenger vehicles). The rules that apply may be different depending on the group involved. Relevant guidelines Assessing fitness to drive: a guide for medical professionals: GMC guidance from Royal College of Psychiatrists guidance from Driving and Mental Health Conditions and Treatments Review June

3 Mental Health Condition and Fitness to Drive ADHD May be able to drive but must notify the DVLA Licensing may continue provided no factors that render driving dangerous Consider factors such as impulsivity, lack of awareness of the impact of own behaviours on self or others need. Anxiety disorders Poor concentration and attention may impair driving. Other symptoms that may affect driving include suicidal ideation. Notify the DVLA only if severe with significant memory and concentration problems, agitation, behavioural disturbance or suicidal thoughts Relicensing will depend on the outcome of the DVLA enquiry Group 2 driver should have recovered and be stable for a period of six months before resuming driving. Bipolar affective disorder: Several symptoms of this disorder may affect driving: suicidal ideation, impaired judgment with over confidence and risk-taking behaviour, poor concentration and attention, etc. Must notify the DVLA and driving must cease Relicensing may be considered if all DVLA conditions met There must be no driving during any acute illness Driving and Mental Health Conditions and Treatments Review June

4 Mental Health Condition and Fitness to Drive - continued Depression: The cognitive impairment caused by severe depression can be important and involves all cognitive abilities including slowing of reaction time. Other symptoms that may affect driving include suicidal ideation In non-complicated, minor or short-lived depressive episodes without significant memory problems, concentration difficulties, agitation, behavioural disturbance or suicidal thoughts, the DVLA need not be notified and driving may continue. However, the effects of medication should be considered. Where there are moderate to severe symptoms of depression: notify the DVLA and stop driving pending the outcome. Driving may only resume following a period of stability of six months for group 2 drivers. Patients should not drive during a course of ECT. Dementias Mild Cognitive Impairment Dementia May drive and need not notify the DVLA but see note below. Notification to the DVLA of mild cognitive impairment is not required unless there are objective indicators of possible driving impairments or a diagnosis of mild dementia, in which case driving must cease pending individual DVLA enquiry. It is difficult to assess driving ability in people with dementia. Progressive deterioration in memory, reactions and perception will interfere with driving skills Notify the DVLA. Depending on the outcome of enquiry, Group 1 drivers may be able to drive but must notify the DVLA. Group 2 drivers must not drive and must notify the DVLA. Licensing will be refused or revoked. Regular formal driving assessments may be necessary Driving and Mental Health Conditions and Treatments Review June

5 Mental Health Condition and Fitness to Drive- continued Neurological Disorders Epilepsy/Seizures Post Head Injury Learning disabilities Mild learning disability Severe learning disability Autism, Asperger s syndrome Personality disorders Epileptic seizures are the most common medical cause of collapse at the wheel. Must not drive and must notify Depending on the circumstances and outcome of DVLA medical enquiry, driving may resume following a period of stability. See DVLA. Must not drive and must notify and await DVLA decision. Licensing will be refused or revoked if there is serious disturbance for example, violent behaviour or alcohol abuse likely to be a source of danger at the wheel Notify DVLA In mild learning disability, provided there are no other relevant problems, it may be possible to hold a driving licence, but it will be necessary to demonstrate adequate functional ability at the wheel. There should not be any comorbid mental or physical illness affecting driving ability. Notify the DVLA and must not drive Severe learning disability is not compatible with driving and licensing will be refuse. May be able to drive but must notify Patients with a diagnosis of autism, Asperger s syndrome may be permitted to drive provided they do not suffer from factors that render driving dangerous. Aggressive and impulsive behaviour may affect driving. Other traits exhibited in these disorder will also interfere eg intolerance or frustration Group 1 drivers may be able to drive but must notify the DVLA and await outcome. Group 2 drivers must not drive and must notify the DVLA and await outcome. Licences will be revoked or refused for patients who suffer from personality disorders with marked impulsivity, as this may affect driving Driving and Mental Health Conditions and Treatments Review June

6 Mental Health Condition and Fitness to Drive - continued Psychosis and Schizophrenia Several symptoms of this disorder may affect driving: suicidal ideation, impaired concentration and memory, impaired judgment, delusions, hallucinations, confused thinking, agitated behaviour, etc. Must notify the DVLA. Driving should cease during any acute illness and will only be considered if all DVLA conditions are met. Group 2 will require a period of wellness and stability before relicensing. Substance Misuse Alcohol Drivers with a history of instability or relapse and/or poor engagement with treatment will be required not to drive for a longer period before any relicensing. Alcohol can affect a driver s behaviour and body in all sorts of dangerous and unpredictable ways. Driving while on the influence of alcohol substances will lead to licence refusal or revocation. Persistent harmful alcohol misuse - Must not drive and must notify the DVLA. A Group 2 licence will only be issued after a stable period of at least one year of abstinence or controlled drinking and at least six months for Group 1 drivers. Alcohol dependence-- Must not drive and must notify the DVLA. A diagnosis of alcohol dependence would normally result in the licence being revoked or refused until a one-year alcohol-free period has been achieved for Group 1 drivers and a three-year period for Group 2 drivers. People with alcohol related disorders like cirrhosis with neuropsychiatric impairment or alcohol-induced psychosis may not drive until recovery is demonstrated satisfactorily. Alcohol related solitary seizure - Must not drive and must notify the DVLA. (If more than 1 seizure, as for epilepsy)license will be refused or revoked for a minimum of six months from the date of the seizure in Group 1 drivers and five years for Group 2 drivers. The stricter epilepsy regulations will apply if there has been more than one seizure. Driving and Mental Health Conditions and Treatments Review June

7 Mental Health Condition and Fitness to Drive - continued Substance Misuse Drug misuse Drug dependence heroin morphine methadone cocaine methamphetamine Must not drive and must notify the DVLA with persistent misuse or dependence. Persistent harmful use of cannabis, amphetamines, ecstasy (MDMA), ketamine, LSD and other hallucinogens will lead to licence refusal or revocation until a minimum six-month period of abstinence has been attained in Group 1 drivers and a minimum one-year period in Group 2 drivers. There are different rules for ketamine. Must not drive and must notify the DVLA with persistent misuse or dependence. Persistent misuse of or dependence on opiates will lead to licence refusal or revocation until a minimum one-year period of abstinence in Group 1 drivers and at least three years in Group 2 drivers. Full compliance with an oral methadone maintenance programme supervised by a consultant specialist may allow licensing subject to favourable assessment and, usually, annual medical review. Similar criteria may apply for an oral buprenorphine programme. There should be no evidence of continued use of other substances, including cannabis. Drug-induced solitary seizure: Must not drive and must notify the DVLA. Licence will be refused or revoked for a minimum of 6 months after the seizure for group 1 and 5 years for group 2 drivers. Benzodiazepines: If a person misuses benzodiazepines or has been prescribed supra-therapeutic doses, a Group 1 licence will be revoked for a period of one year and a Group 2 licence for three years. The prescribed use of these drugs at the therapeutic doses listed in the BNF, without evidence of impairment, does not amount to misuse or dependence for licensing purposes. Driving and Mental Health Conditions and Treatments Review June

8 Psychotropic medication and Fitness to Drive Antipsychotics: Antipsychotics Chlorpromazine, levomepromazine, and promazine Pericyazine and pipotiazine Fluphenazine, perphenazine, prochlorperazine, and trifluoperazine Haloperidol Flupentixol and zuclopentixol Pimozide and sulpiride Clozapine Quetiapine Olanzapine Risperidone Antidepressants Tricyclic antidepressants They may cause varying levels of motor and extrapyramidal adverse effects, sedation and poor concentration. In susceptible individuals, drugs with antimuscarinic may potentially precipitate or worsen glaucoma, blurred vision and mydriasis. Epileptogenic effects should be considered. Pronounced sedative effects and moderate antimuscarinic and extrapyramidal side-effects. They may cause hypotension and blurred vision. Moderate sedative effects and extrapyramidal side-effects Low sedative and antimuscarinic effects, high incidence of extrapyramidal side-effects Low sedative and antimuscarinic effects, high incidence of extrapyramidal side-effects Moderate sedative, antimuscarinic effects, and extrapyramidal effects Reduced sedative, antimuscarinic, and extrapyramidal effects. Hypotension and sedation. Antimuscarinic effects Hypotension and sedation Causes sedation and dizziness Minor or moderate influence on the ability to drive and use machines due to potential nervous system and visual effects Have pronounced anticholinergic and antihistaminic effects. They may cause varying levels of sedation, concentration difficulties and postural hypotension. These symptoms may impair psychomotor skills and therefore driving. In susceptible individuals, drugs with antimuscarinic may potentially precipitate or worsen glaucoma, blurred vision and mydriasis Driving and Mental Health Conditions and Treatments Review June

9 Psychotropic medication and Fitness to Drive (continued) Trazodone Mirtazapine MAOI SSRIs, venlafaxine, duloxetine ECT Mood Stabilisers: Lithium Antiepileptic drugs Antidementia medication: Rivastigmine Donepezil Galantamine Others Benzodiazepines It has sedating properties, it can also cause confusional states and blurred vision Has sedating properties that may affect driving by reducing concentration and alertness Small or no effect on orthostatic hypotension, sedation or psychomotor impairment but like with any psychoactive medicinal product patients should still be cautioned about their ability to drive or operate hazardous machinery. Small or no effect on orthostatic hypotension, sedation or psychomotor impairment but like with any psychoactive medicinal product patients should still be cautioned about their ability to drive or operate hazardous machinery. Consider effects from the ECT treatment itself, from the anaesthesia and from the underlying condition. Driving must stop during an acute course of treatment with ECT and is not permitted until the relevant medical standards and observation periods associated with underlying conditions have been met Lithium slows reaction time and may cause dizziness, memory problems, impaired consciousness and extrapyramidal disorders They may produce CNS-related adverse effects, including dizziness, drowsiness and ataxia. Antiepileptic drugs have been associated with visual effects such as diplopia, blurred vision and impaired eye accommodation. It may induce syncope or delirium. It can induce fatigue, dizziness and muscle cramps It can cause dizziness and somnolence Benzodiazepines are the psychotropic medication most likely to impair driving performance. The effects are particularly severe with the long-acting compounds such as diazepam. Subjected to drug screening driving excess limits from Driving and Mental Health Conditions and Treatments Review June

10 Psychotropic medication and Fitness to Drive (continued) Opioid analgesics Methadone Buprenorphine Zopiclone, zolpidem, zaleplon ADHD medication Bupropion Varenicline Opioids may reduce cognitive performance especially at the start of treatment; cause sedation and affect the driving ability by causing impaired coordination, slow reflexes and miosis and blurred vision. Subject to drug screening driving excess limits from Notify the DVLA. Driving may be allowed while taking methadone, only after regular assessment which will include urine screen for drugs. Subject to drug screening driving excess limits from Notify the DVLA. Driving may be allowed while taking buprenorphine, only after regular assessment which will include urine screen for drugs. They may have residual effects the next day which include sedation, amnesia, impaired concentration and impaired muscular function which may adversely affect the ability to drive. Patient should be advised not to drive if affected. They may have a variety of adverse effects that may impair driving including: dizziness, drowsiness and visual disturbances including difficulties with accommodation, diplopia and blurred vision. Bupropion may impair performance of skilled tasks (e.g. driving) Varenicline may have minor or moderate influence on the ability to drive and use machines. It may cause dizziness and somnolence and therefore may influence the ability to drive and use machines. Patients are advised not to drive, operate complex machinery or engage in other potentially hazardous activities until it is known whether this medicinal product affects their ability to perform these activities. Driving and Mental Health Conditions and Treatments Review June

11 References Assessing fitness to drive: a guide for medical professionals: Driver and Vehicle Licensing Agency (DVLA). Drugs and driving: the law. GMC guidelines at Royal College of Psychiatrists SPCs for all the drugs referred to in this guideline can be found in the Electronic Medicines Compendium ( Driving and Mental Health Conditions and Treatments Review June

DRIVING, DVLA, AND ADVISING PATIENTS: TOP TIPS

DRIVING, DVLA, AND ADVISING PATIENTS: TOP TIPS DRIVING, DVLA, AND ADVISING PATIENTS: TOP TIPS DR IÑIGO PEREZ MEDICAL ADVISER, DVLA GENERAL PRACTICE HOT TOPICS NOTTINGHAM 22 APRIL 2017 OUTLINE Drug driving Epilepsy concessions Fit to drive DRUG DRIVING

More information

Smoking Cessation Pharmacotherapy Guidelines

Smoking Cessation Pharmacotherapy Guidelines Smoking Cessation Pharmacotherapy Guidelines INTRODUCTION This guideline is based on public health guidance 10 Smoking Cessation Services issued by the National Institute for Health and Clinical Excellence

More information

WORCESTERSHIRE MENTAL HEALTH PARTNERSHIP NHS TRUST SUBSTANCE MISUSE AND DRIVING GUIDANCE

WORCESTERSHIRE MENTAL HEALTH PARTNERSHIP NHS TRUST SUBSTANCE MISUSE AND DRIVING GUIDANCE WORCESTERSHIRE MENTAL HEALTH PARTNERSHIP NHS TRUST SUBSTANCE MISUSE AND DRIVING GUIDANCE This policy should be read in conjunction with Worcestershire Mental Health Partnership NHS Trust Policy Data Unique

More information

Driving and Pain. Guidance for Faculty of Pain Medicine Members

Driving and Pain. Guidance for Faculty of Pain Medicine Members Driving and Pain Guidance for Faculty of Pain Medicine Members Introduction Road traffic accidents remain a significant public health problem in the UK. In 2016 there were over 180,000 casualties resulting

More information

Psychotropic Medication Use in Dementia

Psychotropic Medication Use in Dementia Psychotropic Medication Use in Dementia Marie A DeWitt, MD Diplomate of the American Board of Psychiatry and Neurology, Specialization in Psychiatry & Subspecialization in Geriatric Psychiatry Staff Physician,

More information

Mental Health Medicines Management Pilot. Community Pharmacy. High Dose Antipsychotic Screening, Education & Advice Service

Mental Health Medicines Management Pilot. Community Pharmacy. High Dose Antipsychotic Screening, Education & Advice Service Mental Health Medicines Management Pilot Community Pharmacy High Dose Antipsychotic Screening, Education & Advice Service Approved Version 1 Date of First Issue Review Date Date of Issue Author / Contact

More information

Professor Tony Holland, Department of Psychiatry, University of Cambridge

Professor Tony Holland, Department of Psychiatry, University of Cambridge INFORMATION SHEET The Use of Medication for Challenging Behaviour Professor Tony Holland, Department of Psychiatry, University of Cambridge Introduction Challenging behaviours displayed by people with

More information

ACOEM Commercial Driver Medical Examiner Training Program

ACOEM Commercial Driver Medical Examiner Training Program ACOEM Commercial Driver Medical Examiner Training Program Module 7: Psychological Psychological 49 CFR 391.41(b)(9) "A person is physically qualified to drive a commercial motor vehicle if that person

More information

Formulary and Clinical Guideline Document Pharmacy Department Medicines Management Services

Formulary and Clinical Guideline Document Pharmacy Department Medicines Management Services Formulary and Clinical Guideline Document Pharmacy Department Medicines Management Services VIOLENCE, AGGRESSION OR SEVERE BEHAVIOURAL DISTURBANCE Introduction During an acute episode or illness, some

More information

1/26/2016. These are my own thoughts! Safe Workplace Safe Workforce Proven benefits of Stay At Work / Return To Work Process (SAW/RTW)

1/26/2016. These are my own thoughts! Safe Workplace Safe Workforce Proven benefits of Stay At Work / Return To Work Process (SAW/RTW) Dr. Paul A. Farnan farnan@mail.ubc.ca HealthQuest Occupational Health Corporation Alliance Medical Monitoring I have no financial interests or affiliation with any pharmaceutical industry or manufacturer

More information

Treatment Options for Bipolar Disorder Contents

Treatment Options for Bipolar Disorder Contents Keeping Your Balance Treatment Options for Bipolar Disorder Contents Medication Treatment for Bipolar Disorder 2 Page Medication Record 5 Psychosocial Treatments for Bipolar Disorder 6 Module Summary 8

More information

Alcoholism. Psychiatry. Alcoholism. Alcoholism. Certification. Certification

Alcoholism. Psychiatry. Alcoholism. Alcoholism. Certification. Certification Alcoholism Psychiatry Liz Clark, D.O., MPH & TM FAOCOPM MY-2012 Except where absolute criteria exist (i.e., a current clinical diagnosis of alcoholism), as a medical examiner, you make the final determination

More information

Liz Clark, D.O., MPH & TM FAOCOPM

Liz Clark, D.O., MPH & TM FAOCOPM Liz Clark, D.O., MPH & TM FAOCOPM Except where absolute criteria exist (i.e., a current clinical diagnosis of alcoholism), as a medical examiner, you make the final determination as to whether the driver

More information

Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE DRUG: LISDEXAMFETAMINE PROTOCOL NUMBER: CV 57

Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE DRUG: LISDEXAMFETAMINE PROTOCOL NUMBER: CV 57 Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE DRUG: LISDEXAMFETAMINE PROTOCOL NUMBER: CV 57 INDICATION: Attention deficit hyperactivity disorder (ADHD) as part of a

More information

Safe transfer of prescribing guidance

Safe transfer of prescribing guidance Safe transfer of prescribing guidance TEWV Prescriber Summary Application required before prescribing Products requiring an application, before prescribing, using the single application form Unlicensed

More information

GREATER MANCHESTER INTERFACE PRESCRIBING GROUP

GREATER MANCHESTER INTERFACE PRESCRIBING GROUP GREATER MANCHESTER INTERFACE PRESCRIBING GROUP On behalf of the GREATER MANCHESTER MEDICINES MANAGEMENT GROUP SHARED CARE GUIDELINE FOR THE PRESCRIBING OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)

More information

GUIDELINES FOR THE USE OF PSYCHOACTIVE MEDICATIONS IN INDIVIDUALS WITH CO-OCCURRING SUBSTANCE USE DISORDERS

GUIDELINES FOR THE USE OF PSYCHOACTIVE MEDICATIONS IN INDIVIDUALS WITH CO-OCCURRING SUBSTANCE USE DISORDERS City and County of San Francisco Mayor Gavin Newsom Department of Public Health Community Behavioral Health Services 1380 Howard Street 5 th Floor San Francisco, CA 94103 GUIDELINES FOR THE USE OF PSYCHOACTIVE

More information

PROCEDURE REF NO SABP/EXECUTIVE BOARD/0017

PROCEDURE REF NO SABP/EXECUTIVE BOARD/0017 PROCEDURE REF NO SABP/EXECUTIVE BOARD/0017 NAME OF GUIDELINE REASON FOR GUIDELINE WHAT THE GUIDELINE WILL ACHIEVE? WHO NEEDS TO KNOW ABOUT IT? Medicines Guideline: Hypnotic Medication Compliance with NICE

More information

South London and the Maudsley NHS Foundation Trust Medicines Formulary

South London and the Maudsley NHS Foundation Trust Medicines Formulary South London and the Maudsley NHS Foundation Trust Medicines Formulary Medicine Formulations Restrictions Additional Information / Related NICE Technology Appraisal 4.1 Hypnotics and anxiolytics 4.1.1

More information

What is pregabalin? Pregabalin tablets. Pregabalin misuse. National Drug Treatment Centre Research. Administration

What is pregabalin? Pregabalin tablets. Pregabalin misuse. National Drug Treatment Centre Research. Administration What is pregabalin? Pregabalin is a prescription drug used to manage a number of long-term conditions, including epilepsy, neuropathic pain and generalised anxiety disorder. Similar to benzodiazepines,

More information

Benzodiazepines: risks, benefits or dependence

Benzodiazepines: risks, benefits or dependence Benzodiazepines: risks, benefits or dependence A re-evaluation Council Report CR 59 January 1997 Royal College of Psychiatrists, London Due for review: January 2002 1 Contents A College Statement 3 Benefits

More information

Pregnancy. General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition)

Pregnancy. General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition) Pregnancy General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition) In all women of child bearing potential Always discuss the possibility of pregnancy; half of all pregnancies are unplanned

More information

MERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES. MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) KEY ISSUES

MERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES. MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) KEY ISSUES MERSEY CARE NHS TRUST HOW WE MANAGE MEDICINES MM11 - High-Dose Antipsychotic Use Guidelines (local guideline) Medicines Management Services aim to ensure that (i) Service users receive their medicines

More information

DRIVING, DVLA, AND ADVISING PATIENTS: TOP TIPS

DRIVING, DVLA, AND ADVISING PATIENTS: TOP TIPS DRIVING, DVLA, AND ADVISING PATIENTS: TOP TIPS DR IÑIGO PEREZ MEDICAL ADVISER, DVLA GENERAL PRACTICE HOT TOPICS LIVERPOOL 4 FEBRUARY 2017 OUTLINE Case Scenarios Fit to fly X Fit to drive Drug driving Epilepsy

More information

SHARED CARE GUIDELINE

SHARED CARE GUIDELINE SHARED CARE GUIDELINE Title: Shared Care Guideline for the prescribing and monitoring of Antipsychotics for the treatment of Schizophrenia and psychotic symptoms in children and adolescents Scope: Pennine

More information

SiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA. [compatible with NICE guidance]

SiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA. [compatible with NICE guidance] SiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA [compatible with NICE guidance] Medicines Management Committee August 2002 For review August 2003 Rationale The SiGMA algorithm

More information

A Basic Approach to Mood and Anxiety Disorders in the Elderly

A Basic Approach to Mood and Anxiety Disorders in the Elderly A Basic Approach to Mood and Anxiety Disorders in the Elderly November 1 2013 Sarah Colman MD FRCPC Clinical Fellow, Geriatric Psychiatry Mount Sinai Hospital, University of Toronto Disclosure No conflict

More information

Condensed Clinical Practice Guideline Treatment Of Patients With Schizophrenia

Condensed Clinical Practice Guideline Treatment Of Patients With Schizophrenia Condensed Clinical Practice Guideline Treatment Of Patients With Schizophrenia I. Key Points a. Schizophrenia is a chronic illness affecting all aspects of person s life i. Treatment Planning Goals 1.

More information

SUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS

SUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS SUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS Guideline Title Summary of Product Characteristics for Benzodiazepines as Anxiolytics or Hypnotics Legislative basis Directive

More information

This factsheet covers:

This factsheet covers: Antipsychotics If you experience psychosis as part of your illness, you may be offered antipsychotic medication. Antipsychotics are generally used to treat psychosis, but are also used to treat bipolar

More information

Olanzapine Long-Acting Injection (Zypadhera ) - Guidelines for Prescribing and Administration (Version 3 May 2015)

Olanzapine Long-Acting Injection (Zypadhera ) - Guidelines for Prescribing and Administration (Version 3 May 2015) 1. Key Points Olanzapine Long-Acting Injection (Zypadhera ) - Guidelines for Prescribing and Administration (Version 3 May 2015) 1.1 Olanzapine long acting injection (LAI) is indicated for the maintenance

More information

SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION

SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION Naltrexone is used as part of a comprehensive programme of treatment against alcoholism to reduce the

More information

You will be prescribed a preparation in the strength of 1mg/1ml. Methadone, like heroin can also cause a physical dependence.

You will be prescribed a preparation in the strength of 1mg/1ml. Methadone, like heroin can also cause a physical dependence. METHADONE LEAFLET: What is Methadone? Methadone is a synthetic drug, used in the treatment of people who have a physical dependence to opiates, thereby preventing the onset of opiate withdrawal symptoms

More information

Perinatal Mental Health: Prescribing Guidance for Trust Prescribers and GPs

Perinatal Mental Health: Prescribing Guidance for Trust Prescribers and GPs Perinatal Mental Health: Prescribing Guidance for Trust Prescribers and GPs (Version 3 January 2015) Principal Author: Dr Jenny Cooke Consultant Psychiatrist, Brighton & Hove Perinatal Mental Health Service

More information

BEHAVIORAL PROBLEMS IN DEMENTIA

BEHAVIORAL PROBLEMS IN DEMENTIA BEHAVIORAL PROBLEMS IN DEMENTIA CLINICAL FEATURES Particularly as dementia progresses, psychiatric symptoms may develop that resemble discrete mental disorders such as depression or mania The course and

More information

This document has been produced in collaboration with the Lancashire Commissioning Support Unit

This document has been produced in collaboration with the Lancashire Commissioning Support Unit Joint for Psychotropic Medication. This document has been produced in collaboration with the Lancashire Commissioning Support Unit Date: December 2014. Reviewed August 2016. Next review Date April 2019

More information

RESPONSE TO THE DEPARTMENT FOR TRANSPORT S CONSULTATION PAPER

RESPONSE TO THE DEPARTMENT FOR TRANSPORT S CONSULTATION PAPER RESPONSE TO THE DEPARTMENT FOR TRANSPORT S CONSULTATION PAPER REGULATIONS TO SPECIFY THE DRUGS AND CORRESPONDING LIMITS FOR THE NEW OFFENCE OF DRIVING WITH A SPECIFIED CONTROLLED DRUG IN THE BODY ABOVE

More information

Psychotropic Drug Therapy in Adults with Learning Disability. Steve Wilkinson

Psychotropic Drug Therapy in Adults with Learning Disability. Steve Wilkinson Psychotropic Drug Therapy in Adults with Learning Disability Steve Wilkinson Outline and Aims of the Session Drug use in learning disability Two distinct areas of drug therapy I. Treatment of common psychiatric

More information

Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services

Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services DEPRESSION Pharmacological Treatment of Depression NICE guidelines suggest the following stepped care model also

More information

PRESCRIBING GUIDELINES

PRESCRIBING GUIDELINES The Maudsley The South London and Maudsley NHS Foundation Trust & Oxleas NHS Foundation Trust PRESCRIBING GUIDELINES 10th Edition David Taylor Carol Paton Shitij Kapur informa healthcare Contents Authors

More information

ASAM Criteria, Third Edition Matrix for Matching Adult Severity and Level of Function with Type and Intensity of Service

ASAM Criteria, Third Edition Matrix for Matching Adult Severity and Level of Function with Type and Intensity of Service 1: Acute Intoxication and/or Withdrawal Potential Risk Rating: 0 1: Acute Intoxication and/or Withdrawal Potential Risk Rating: 1 1: Acute Intoxication and/or Withdrawal Potential Risk Rating: 2 The patient

More information

Formulary Item Restrictions and/or Advice Site availability

Formulary Item Restrictions and/or Advice Site availability Formulary Item Restrictions and/or Advice Site availability C&W CNWL Typical Antipsychotic drugs Chlorpromazine 25mg Chlorpromazine 50mg Chlorpromazine 100mg Chlorpromazine 25mg/5ml syrup Chlorpromazine

More information

Atomoxetine Effective Shared Care Agreement For Attention Deficit Hyperactivity Disorder (ADHD)

Atomoxetine Effective Shared Care Agreement For Attention Deficit Hyperactivity Disorder (ADHD) Atomoxetine Effective Shared Care Agreement For Attention Deficit Hyperactivity Disorder (ADHD) Section 1: Shared Care arrangements and responsibilities Section 1.1 Agreement to transfer of prescribing

More information

Glencoe Health. Lesson 3 Psychoactive Drugs

Glencoe Health. Lesson 3 Psychoactive Drugs Glencoe Health Lesson 3 Psychoactive Drugs Health espotlight Video BIG IDEA Psychoactive drugs affect the central nervous system and can be especially damaging to the developing brain and body of a teen.

More information

Joint Formulary for Psychotropic Medication.

Joint Formulary for Psychotropic Medication. Joint for Psychotropic Medication. This document has been produced in collaboration with the Lancashire Commissioning Support Unit Page 1 Table of Contents Section Page Number Page 2 Definition of categories

More information

Use of Psychotropic Medications in Older Adults with Dementia!

Use of Psychotropic Medications in Older Adults with Dementia! Use of Psychotropic Medications in Older Adults with Dementia! Deepa Pattani, PharmD, RPh Owner: PrevInteract Health Deepa.Pattani@PrevInteract.com 972-372-9775 About Me Deepa Pattani, PharmD, RPh with

More information

High Dose Antipsychotic Therapy (HDAT) guideline

High Dose Antipsychotic Therapy (HDAT) guideline Document level: Trustwide (TW) Code: MP18 Issue number: 2 High Dose Antipsychotic Therapy (HDAT) guideline Lead executive Medical Director Author and contact number Lead Clinical Pharmacist 01625 663 857

More information

Guidelines MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD)

Guidelines MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD) MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD) Guidelines CH Lim, B Baizury, on behalf of Development Group Clinical Practice Guidelines Management of Major Depressive Disorder A. Introduction Major depressive

More information

Guidance on Consent to Treatment Documentation for Medication Patient s Detained under the Mental Health Act

Guidance on Consent to Treatment Documentation for Medication Patient s Detained under the Mental Health Act Guidance on Consent to Treatment Documentation for Medication Patient s Detained under the Mental Health Act This guidance is intended for Coventry and Warwickshire Partnership Trust staff to use when

More information

DRUG RELATED DEATHS AND PREGABALIN. Dr Abhishek Goli INSPIRE CGL

DRUG RELATED DEATHS AND PREGABALIN. Dr Abhishek Goli INSPIRE CGL DRUG RELATED DEATHS AND PREGABALIN Dr Abhishek Goli INSPIRE CGL INTRODUCTION 1. Overview on drug related deaths 2. Pregabalin and Gabapentin abuse potential 3. Benzos POTENTIAL FACTORS Increase in availability

More information

Drugs and Alcohol Abuse Policy

Drugs and Alcohol Abuse Policy Drugs and Alcohol Abuse Policy Introduction From the beginning of 2013, there are increased requirements to provide mandatory proof of inhouse drugs and alcohol testing procedures prior to employees being

More information

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. Introduction. Parkinson's disease (PD) has been considered largely as a motor disorder. It has been increasingly recognized that

More information

PSYCHOTROPIC MEDICATION AND THE WORKPLACE. Dr. Marty Ewer 295 Fullarton Road Parkside

PSYCHOTROPIC MEDICATION AND THE WORKPLACE. Dr. Marty Ewer 295 Fullarton Road Parkside PSYCHOTROPIC MEDICATION AND THE WORKPLACE Dr. Marty Ewer 295 Fullarton Road Parkside 5063 82999281 Introduction Depression and anxiety commonly occur in people who work. The World Health Organization has

More information

Bournemouth, Dorset and Poole Prescribing Forum

Bournemouth, Dorset and Poole Prescribing Forum SHARED CARE GUIDELINES FOR PRESCRIBING OF METHYLPHENIDATE IN ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN INDICATION Methylphenidate is generally regarded as a first line choice of treatment for

More information

Prescribing framework for Dexamfetamine for Attention Deficit Hyperactive Disorder

Prescribing framework for Dexamfetamine for Attention Deficit Hyperactive Disorder Hull & East Riding Prescribing Committee Prescribing Framework for Dexamfetamine for Attention Deficit Hyperactive Disorder Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker)

More information

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics. DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this

More information

UNIVERSITY STATEMENT FOR STUDENTS ON SUBSTANCE USE/MISUSE

UNIVERSITY STATEMENT FOR STUDENTS ON SUBSTANCE USE/MISUSE UNIVERSITY STATEMENT FOR STUDENTS ON SUBSTANCE USE/MISUSE HEALTH & SAFETY UNIT AUTUMN 2012 CONTENTS 1 AIM... 2 2 APPLICATION... 2 3 DEFINITIONS... 2 4 EDUCATION AND AWARENESS RAISING... 2 5 PROVISION OF

More information

NSFT Formulary. Double Red Not recommended for routine use/not commissioned. These drugs have not been recommended for routine use at present.

NSFT Formulary. Double Red Not recommended for routine use/not commissioned. These drugs have not been recommended for routine use at present. Traffic Light Status NSFT Formulary Not recommended for routine use/not commissioned. These drugs have not been recommended for routine use at present. Hospital/Specialist only Drugs for which the Trust

More information

Antipsychotic Medications

Antipsychotic Medications TRAIL: Team Review of EVIDENCE REVIEW & RECOMMENDATIONS FOR LTC Behavioural and psychological symptoms of dementia (BPSD) refer to the non-cognitive symptoms of disturbed perception, thought content, mood

More information

M0BCore Safety Profile. Active substance: Bromazepam Pharmaceutical form(s)/strength: Tablets 6 mg FR/H/PSUR/0066/001 Date of FAR:

M0BCore Safety Profile. Active substance: Bromazepam Pharmaceutical form(s)/strength: Tablets 6 mg FR/H/PSUR/0066/001 Date of FAR: M0BCore Safety Profile Active substance: Bromazepam Pharmaceutical form(s)/strength: Tablets 6 mg P-RMS: FR/H/PSUR/0066/001 Date of FAR: 26.11.2013 4.3 Contraindications Bromazepam must not be administered

More information

European PSUR Work Sharing Project CORE SAFETY PROFILE. Lendormin, 0.25mg, tablets Brotizolam

European PSUR Work Sharing Project CORE SAFETY PROFILE. Lendormin, 0.25mg, tablets Brotizolam European PSUR Work Sharing Project CORE SAFETY PROFILE Lendormin, 0.25mg, tablets Brotizolam 4.2 Posology and method of administration Unless otherwise prescribed by the physician, the following dosages

More information

Driving Under the Influence - of Allergy Medicine

Driving Under the Influence - of Allergy Medicine IDEAi.EASE " DOB Driving Under the Influence - of Allergy Medicine With allergy season officially starting, you should be aware that some over-thecounter allergy drugs can seriously impair your ability

More information

Core Safety Profile. Pharmaceutical form(s)/strength: Tablets 5 mg and 10 mg BE/H/PSUR/0002/002 Date of FAR:

Core Safety Profile. Pharmaceutical form(s)/strength: Tablets 5 mg and 10 mg BE/H/PSUR/0002/002 Date of FAR: Core Safety Profile Active substance: Clotiazepam Pharmaceutical form(s)/strength: Tablets 5 mg and 10 mg P-RMS: BE/H/PSUR/0002/002 Date of FAR: 16.06.2011 4.3 Contraindications is contraindicated

More information

Nursing Process Focus: Patients Receiving Chlorpromazine (Thorazine)

Nursing Process Focus: Patients Receiving Chlorpromazine (Thorazine) Nursing Process Focus: Patients Receiving Chlorpromazine (Thorazine) Potential Nursing Diagnoses Ineffective Therapeutic Regimen Management Risk for Activity Intolerance, related to side effect of drug

More information

Main Questions. Why study addiction? Substance Use Disorders, Part 1 Alecia Schweinsburg, MA Abnromal Psychology, Fall Substance Use Disorders

Main Questions. Why study addiction? Substance Use Disorders, Part 1 Alecia Schweinsburg, MA Abnromal Psychology, Fall Substance Use Disorders Substance Use Disorders Main Questions Why study addiction? What is addiction? Why do people become addicted? What do alcohol and drugs do? How do we treat substance use disorders? Why study addiction?

More information

The Art of being Human

The Art of being Human Science - Year 6 Animals including Humans Block 6AH The Art of being Human Session 6 Resource pack Original resource copyright Hamilton Trust, who give permission for it to be adapted as wished by individual

More information

13/09/2018. Syncope & Driving. Risk Syncope during Driving. Risk of Recurrence Syncope

13/09/2018. Syncope & Driving. Risk Syncope during Driving. Risk of Recurrence Syncope Risk Syncope during Driving & Motor Vehicle Crash (MVC) Syncope & Driving Declan Whelan FRCPI; FFOM RCPI. March 2018 Danish Cohort Study: JAMA Intern. Med. 2016: 176(4):503-510. 41,039patients with 1 st

More information

Pharmacy Medical Necessity Guidelines: Antipsychotic Medications

Pharmacy Medical Necessity Guidelines: Antipsychotic Medications Pharmacy Medical Necessity Guidelines: Antipsychotic Medications Effective: July. 1, 2016 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy

More information

Reduce hunger and help control cravings with CONTRAVE

Reduce hunger and help control cravings with CONTRAVE Reduce hunger and help control cravings with CONTRAVE Understanding and identifying patients who are ready to start their weight-loss journey with CONTRAVE is key to helping them reach their weight-loss

More information

The Deprescribing of Psychotropic Medication in Service Users (Patients) with Learning Disability

The Deprescribing of Psychotropic Medication in Service Users (Patients) with Learning Disability The Deprescribing of Psychotropic Medication in Service Users (Patients) with Learning Disability Danielle Adams Principal Clinical Pharmacist Pharmacy and Medicines Optimisation Team HPFT July 2017 1

More information

Chapter 161 Antipsychotics

Chapter 161 Antipsychotics Chapter 161 Antipsychotics Episode Overview Extrapyramidal syndromes are a common complication of antipsychotic medications. First line treatment is benztropine or diphenhydramine. Lorazepam is used in

More information

patient group direction

patient group direction DIAZEPAM (RECTAL) v01 1/8 DIAZEPAM (RECTAL) PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care

More information

Medicines Protocol RECTAL DIAZEPAM

Medicines Protocol RECTAL DIAZEPAM Medicines Protocol RECTAL DIAZEPAM RECTAL DIAZEPAM v2.0 1/6 Protocol Details Version 2.0 Legal category Staff grades POM Registered Paramedic Registered Nurse Specialist Paramedic (Urgent and Emergency

More information

Prescribing medications for people with a personality disorder A service evaluation of a community mental health team

Prescribing medications for people with a personality disorder A service evaluation of a community mental health team Prescribing medications for people with a personality disorder A service evaluation of a community mental health team Dr Umama Khan, Consultant Psychiatrist Dr Venkatesh Ballagere, Specialist Registrar

More information

Controlled Substance and Wellness Agreement

Controlled Substance and Wellness Agreement Controlled Substance and Wellness Agreement You and your provider have agreed on the use of controlled substance medications to treat your: We want to make sure you know how to manage your new prescription(s)

More information

Bournemouth, Dorset and Poole Prescribing Forum

Bournemouth, Dorset and Poole Prescribing Forum SHARED CARE GUIDELINE FOR THE USE OF ATOMOXETINE IN ADULTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER INDICATION Atomoxetine is a non-stimulant non-amphetamine inhibitor of noradrenaline reuptake. It

More information

Document Title Antipsychotics Prescribing Guidelines for Schizophrenia

Document Title Antipsychotics Prescribing Guidelines for Schizophrenia Document Title Antipsychotics Prescribing Guidelines for Schizophrenia Document Description Document Type Prescribing Guidance Service Application Medicines Management Version 1.0 Policy Reference no.

More information

Shared Care Framework for Dexamfetamine the treatment of ADHD in Adults Date approved by Joint Medicines Operational Group 1/12/17

Shared Care Framework for Dexamfetamine the treatment of ADHD in Adults Date approved by Joint Medicines Operational Group 1/12/17 This policy statement is approved by Southport and Formby, and South Sefton CCGs Southport and Formby South Sefton Shared Care Framework for Dexamfetamine the treatment of ADHD in Adults Date approved

More information

SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE

SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE INDICATION Naltrexone is a pure opiate antagonist licensed as an adjunctive prophylactic therapy in the maintenance

More information

SHARED CARE GUIDELINE

SHARED CARE GUIDELINE SHARED CARE GUIDELINE Shared Care Guideline for the prescribing and monitoring of antipsychotics for the treatment of Neurodevelopmental Disorders in children and adolescents. Scope: Version 1 Pennine

More information

Professor Tony Holland, Department of Psychiatry, University of Cambridge

Professor Tony Holland, Department of Psychiatry, University of Cambridge INFORMATION SHEET The Use of Medication in the Treatment of Challenging Behaviour Professor Tony Holland, Department of Psychiatry, University of Cambridge Introduction The use of medication is but one

More information

Medications for Anxiety & Behavior in Williams Syndrome. Disclosure of Potential Conflicts. None 9/22/2016. Evaluation

Medications for Anxiety & Behavior in Williams Syndrome. Disclosure of Potential Conflicts. None 9/22/2016. Evaluation Medications for Anxiety & Behavior in Williams Syndrome Christopher J. McDougle, M.D. Director, Lurie Center for Autism Professor of Psychiatry and Pediatrics Massachusetts General Hospital and MassGeneral

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium olanzapine 210mg, 300mg, 405mg powder and solvent for prolonged release suspension for injection (ZypAdhera ) No. (624/10) Eli Lilly and Company Limited 09 July 2010 The Scottish

More information

Norpramin (desipramine)

Norpramin (desipramine) Generic name: Desipramine Available strengths: 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg tablets Available in generic: Yes Drug class: Tricyclic antidepressant General Information Norpramin (desipramine)

More information

Best Practices in Prescribing Benzodiazepines. Michael Carlisle, DO Medical Director University Hospitals Geauga Medical Center

Best Practices in Prescribing Benzodiazepines. Michael Carlisle, DO Medical Director University Hospitals Geauga Medical Center Best Practices in Prescribing Benzodiazepines Michael Carlisle, DO Medical Director University Hospitals Geauga Medical Center Objectives To review current practice guidelines in benzodiazepine prescribing

More information

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see: bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest

More information

Common poly-substance abuse: MDMA, Ketamine, & Methamphetamine Clinical detection and management

Common poly-substance abuse: MDMA, Ketamine, & Methamphetamine Clinical detection and management Common poly-substance abuse: MDMA, Ketamine, & Methamphetamine Clinical detection and management Prepared by Dr. S.P. LEUNG Castle Peak Hospital 27th January 2001 Medical practitioner should provide care

More information

Medicine Related Falls Risk Assessment Tool (MRFRAT)

Medicine Related Falls Risk Assessment Tool (MRFRAT) Medicine Related Falls Risk Assessment Tool (MRFRAT) The Medicine Related Falls Risk Assessment tool (MRFRAT) in Appendix 1 is designed to help identify patients at risk of falls due to their current medicine

More information

Stop smoking products guidance

Stop smoking products guidance Stop smoking products guidance Ref: Status: Approved Stop smoking products guidance Page 1 of 15 Approval date: 22 November 2018 Contents 1. Purpose... 3 2. Related documents... 3 3. Guidance... 3 3.1

More information

Clinical guideline Published: 24 September 2008 nice.org.uk/guidance/cg72

Clinical guideline Published: 24 September 2008 nice.org.uk/guidance/cg72 Attention deficit hyperactivity disorder: diagnosis and management Clinical guideline Published: 24 September 2008 nice.org.uk/guidance/cg72 NICE 2018. All rights reserved. Subject to Notice of rights

More information

Delirium. Quick reference guide. Issue date: July Diagnosis, prevention and management

Delirium. Quick reference guide. Issue date: July Diagnosis, prevention and management Issue date: July 2010 Delirium Diagnosis, prevention and management Developed by the National Clinical Guideline Centre for Acute and Chronic Conditions About this booklet This is a quick reference guide

More information

Intro to Concurrent Disorders

Intro to Concurrent Disorders CSAM-SCAM Fundamentals Intro to Concurrent Disorders Presentation provided by Jennifer Brasch, MD, FRCPC Psychiatrist, Concurrent Disorders Program, St. Joseph s Healthcare There are all kinds of addicts,

More information

SUBOXONE (buprenorphine and naloxone) sublingual film (CIII) IMPORTANT SAFETY INFORMATION

SUBOXONE (buprenorphine and naloxone) sublingual film (CIII) IMPORTANT SAFETY INFORMATION SUBOXONE (buprenorphine and naloxone) sublingual film (CIII) IMPORTANT SAFETY INFORMATION What is the most important information I should know about SUBOXONE Film? Keep SUBOXONE Film in a secure place

More information

Depression in adults: treatment and management

Depression in adults: treatment and management 1 2 3 4 Depression in adults: treatment and management 5 6 7 8 Appendix V3: recommendations that have been deleted of changed from 2009 guideline Depression in adults: Appendix V3 1 of 22 1 Recommendations

More information

Elavil (amitriptyline)

Elavil (amitriptyline) Generic name: Amitriptyline Available strengths: 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg tablets; 10 mg/ml injection Available in generic: Yes Drug class: Tricyclic antidepressant General Information

More information

Antipsychotics. This factsheet covers -

Antipsychotics. This factsheet covers - Antipsychotics If you experience psychosis as part of an illness, you may be offered antipsychotic medication. Antipsychotics are generally used to treat psychosis, but are also used to treat bipolar disorder

More information

The treatment of bipolar disorder in adults, children and adolescents

The treatment of bipolar disorder in adults, children and adolescents DRAFT FOR CONSULTATION The treatment of bipolar disorder in adults, children and adolescents The paragraphs in the draft are numbered for the purposes of consultation. The final version will not contain

More information

ADVANCED BEHAVIORAL HEALTH, INC. Clinical Level of Care Guidelines

ADVANCED BEHAVIORAL HEALTH, INC. Clinical Level of Care Guidelines The Clinical Level of Care Guidelines contained on the following pages have been developed as a guide to assist care managers, physicians and providers in making medical necessity decisions about the least

More information

Pamelor (nortriptyline)

Pamelor (nortriptyline) Generic name: Nortriptyline Available strengths: 10 mg, 25 mg, 50 mg, 75 mg capsules; 10 mg/5 ml oral solution Available in generic: Yes Drug class: Tricyclic antidepressant General Information Pamelor

More information

Antidepressants. Dr Malek Zihlif

Antidepressants. Dr Malek Zihlif Antidepressants The optimal use of antidepressant required a clear understanding of their mechanism of action, pharmacokinetics, potential drug interaction and the deferential diagnosis of psychiatric

More information